BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36927843)

  • 21. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    Am J Clin Dermatol; 2017 Aug; 18(4):583-590. PubMed ID: 28342016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deep Learning-Based Psoriasis Assessment: Harnessing Clinical Trial Imaging for Accurate Psoriasis Area Severity Index Prediction.
    Xing Y; Zhong S; Aronson SL; Rausa FM; Webster DE; Crouthamel MH; Wang L
    Digit Biomark; 2024; 8(1):13-21. PubMed ID: 38440046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
    Jacobson CC; Kimball AB
    Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
    Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
    Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigating the clinical implication of corneometer and mexameter readings towards objective, efficient evaluation of psoriasis vulgaris severity.
    Hsu CK; Cheng NY; Yang CC; Yen YY; Tseng SH
    Sci Rep; 2022 May; 12(1):7469. PubMed ID: 35523995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intra- and interobserver variability of image-based PASI assessments in 120 patients suffering from plaque-type psoriasis.
    Fink C; Alt C; Uhlmann L; Klose C; Enk A; Haenssle HA
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1314-1319. PubMed ID: 29569769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Automated, computer-guided PASI measurements by digital image analysis versus conventional physicians' PASI calculations: study protocol for a comparative, single-centre, observational study.
    Fink C; Uhlmann L; Klose C; Haenssle HA
    BMJ Open; 2018 May; 8(5):e018461. PubMed ID: 29773695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States.
    Feldman SR; Regnier SA; Chirilov A; Hey F; Gilloteau I; Cella D
    J Am Acad Dermatol; 2019 Jun; 80(6):1650-1657. PubMed ID: 30703461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of an Algorithm for Automated, Computer-Guided PASI Measurements by Digital Image Analysis.
    Fink C; Fuchs T; Enk A; Haenssle HA
    J Med Syst; 2018 Nov; 42(12):248. PubMed ID: 30390142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients.
    Louden BA; Pearce DJ; Lang W; Feldman SR
    Dermatol Online J; 2004 Oct; 10(2):7. PubMed ID: 15530297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inter-observer reliability of the PASI in a clinical setting.
    Cabrera S; Chinniah N; Lock N; Cains GD; Woods J
    Australas J Dermatol; 2015 May; 56(2):100-2. PubMed ID: 25753553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
    Mattei PL; Corey KC; Kimball AB
    J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature.
    Puzenat E; Bronsard V; Prey S; Gourraud PA; Aractingi S; Bagot M; Cribier B; Joly P; Jullien D; Le Maitre M; Paul C; Richard-Lallemand MA; Ortonne JP; Aubin F
    J Eur Acad Dermatol Venereol; 2010 Apr; 24 Suppl 2():10-6. PubMed ID: 20443995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment.
    Chow C; Simpson MJ; Luger TA; Chubb H; Ellis CN
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1406-14. PubMed ID: 25917315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
    Pickard AS; Gooderham M; Hartz S; Nicolay C
    J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Objective assessment of psoriasis erythema for PASI scoring.
    Ahmad Fadzil MH; Ihtatho D; Mohd Affandi A; Hussein SH
    J Med Eng Technol; 2009; 33(7):516-24. PubMed ID: 19639508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic capacity of skin tumor artificial intelligence-assisted decision-making software in real-world clinical settings.
    Li CX; Fei WM; Shen CB; Wang ZY; Jing Y; Meng RS; Cui Y
    Chin Med J (Engl); 2020 Sep; 133(17):2020-2026. PubMed ID: 32810047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.
    Bruins FM; Bronckers IMGJ; Groenewoud HMM; van de Kerkhof PCM; de Jong EMGJ; Seyger MMB
    JAMA Dermatol; 2020 Jan; 156(1):72-78. PubMed ID: 31774449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.